Busey Bank Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Busey Bank trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,490 shares of the biopharmaceutical company’s stock after selling 73 shares during the quarter. Busey Bank’s holdings in Regeneron Pharmaceuticals were worth $1,061,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. NewEdge Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 6.3% in the second quarter. NewEdge Advisors LLC now owns 4,368 shares of the biopharmaceutical company’s stock valued at $4,591,000 after acquiring an additional 260 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Regeneron Pharmaceuticals by 16.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,821 shares of the biopharmaceutical company’s stock valued at $4,016,000 after purchasing an additional 536 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 8.0% during the second quarter. B. Riley Wealth Advisors Inc. now owns 1,086 shares of the biopharmaceutical company’s stock valued at $1,142,000 after acquiring an additional 80 shares in the last quarter. Clearbridge Investments LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $1,506,000. Finally, Prio Wealth Limited Partnership bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $210,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on REGN. Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $683.08 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock has a market cap of $75.06 billion, a price-to-earnings ratio of 16.90, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10. The firm has a 50-day moving average of $723.36 and a two-hundred day moving average of $928.61. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.